Os Vários Tipos de Angioedema: Classificação, Diagnóstico e Tratamento
Resumo
Angioedema caracteriza-se por edema transitório e localizado da derme e submucosa secundário à libertação de mediadores vasoativos de origem mastocitária ou não. Podem também ser formas agudas ou crónicas, hereditárias ou aquiridas. Os aspectos clínicos, em particular nos sintomas associados, e os mecanismos fisiopatológicos subjacentes a cada tipo de angioedema são distintos, devendo os dermatologistas estar capacitados para o seu reconhecimento uma vez que cada um implica diferentes abordagens diagnósticas e terapêuticas, e distintos prognósticos. Este artigo revê a classificação, o diagnóstico e o tratamento dos diferentes tipos de angioedema.
Downloads
Referências
Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602-616. doi:10.1111/all.12380
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393-1414. doi:10.1111/all.13397
Mansi M, Zanichelli A, Coerezza A, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277:585-593. doi:10.1111/joim.12304
Kelly M, Donnelly JP, McAnnally JR, et al. National estimates of emergency department visits for angioedema and allergic reactions in the United States. Allergy Asthma Proc. 2013;34:150-154. doi:10.2500/aap.2013.34.3640
Zilberberg MD, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc. 2010;31:511-519. doi:10.2500/aap.2010.31.3403
Zilberberg MD, Nathanson BH, Jacobsen T, et al. Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007. Allergy Asthma Proc. 2011;32:390-394. doi:10.2500/aap.2011.32.3478
Jolles S, Williams P, Carne E, et al. A UK national audit of hereditary and acquired angioedema. Clin Exp Immunol. 2014;175:59-67. doi:10.1111/cei.12159
Ikizoglu G. Red face revisited: Flushing. Clin Dermatol. 2014;32:800-808. doi:10.1016/j.clindermatol.2014.02.019
Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci. 1994;87:567-574.
Nussberger J, Cugno M, Cicardi M. Bradykinin-mediated angioedema. N Engl J Med. 2002;347:621-622. doi:10.1056/nejm200208223470820
Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139:1772-1781.e1. doi:10.1016/j.jaci.2016.08.050
Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. Cmaj. 2006;175:1065-1070. doi:10.1503/cmaj.060535
Magen E, Mishal J, Zeldin Y, et al. Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticaria. Allergy Asthma Proc. 2011;32:460-466. doi:10.2500/aap.2011.32.3483
Miller DR, Oliveria SA, Berlowitz DR, et al. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51:1624-1630. doi:10.1161/HYPERTENSIONAHA.108.110270
Brown NJ, Ray WA, Snowden M, et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13. doi:10.1016/s0009-9236(96)90161-7
Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642. doi:10.1001/archinte.165.14.1637
Burkhart DG, Brown NJ, Griffin MR, et al. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiol Drug Saf. 1996;5:149-154. doi:10.1002/(sici)1099-1557(199605)5:3<149::Aid-pds222>3.0.Co;2-i
Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med. 2012;172:1582-1589. doi:10.1001/2013.jamainternmed.34
Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103-111.
Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. Jama. 1997;278:232-233.
Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology. 1999;44:21-25.
Slater EE, Merrill DD, Guess HA, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. Jama. 1988;260:967-970.
Campo P, Fernandez TD, Canto G, et al. Angioedema induced by angiotensin-converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13:337-344. doi:10.1097/ACI.0b013e328362b835
Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci. 2001;46:1239-1243.
Cupido C, Rayner B. Life-threatening angio-oedema and death associated with the ACE inhibitor enalapril. S Afr Med J. 2007;97:244-245.
Messerli FH, Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet. 2000;356:608-609. doi:10.1016/s0140-6736(00)02596-4
Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med. 2010;56:278-282. doi:10.1016/j.annemergmed.2010.03.032
Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35:e60. doi:10.2337/dc12-0574
Faisant C, Armengol G, Bouillet L, et al. Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database. J Clin Immunol. 2016;36:95-102. doi:10.1007/s10875-015-0228-3
Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens. 2011;29:2273-2277. doi:10.1097/HJH.0b013e32834b4b9b
Hahn J, Trainotti S, Hoffmann TK, et al. Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report. Am J Case Rep. 2017;18:576-579.
Hauptmann G, Lang JM, North ML, et al. Acquired c1-inhibitor deficiencies in lymphoproliferative diseases with serum immunoglobulin abnormalities. A study of three cases. Blut. 1976;32:195-206.
Caldwell JR, Ruddy S, Schur PH, et al. Acquired C1 inhibitor deficiency in lymphosarcoma. Clin Immunol Immunopathol. 1972;1:39-52. doi:https://doi.org/10.1016/0090-1229(72)90006-2
Schreiber AD, Zweiman B, Atkins P, et al. Acquired angioedema with lymphoproliferative disorder: association of C1 inhibitor deficiency with cellular abnormality. Blood. 1976;48:567-580.
Hauptmann G, Petitjean F, Lang JM, et al. Acquired C1 inhibitor deficiency in a case of lymphosarcoma of the spleen. Reversal of complement abnormalities after splenectomy. Clin Exp Immunol. 1979;37:523-531.
Cugno M, Cicardi M, Coppola R, et al. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology. 1996;33:361-364.
Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. 1997;89:3213-3218.
Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697. doi:10.1016/s0140-6736(97)09137-x
Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010;6:14. doi:10.1186/1710-1492-6-14
Cicardi M, Zanichelli A. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Curr Mol Med. 2010;10:354-360.
Bouillet-Claveyrolas L, Ponard D, Drouet C, et al. Clinical and biological distinctions between type I and type II acquired angioedema. Am J Med. 2003;115:420-421.
Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. J Allergy Clin Immunol. 2013;131:1491-1493. doi:10.1016/j.jaci.2013.03.034
Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Med. 1992;71:206-215.
Zanichelli A, Bova M, Coerezza A, et al. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy. 2012;67:1074-1077. doi:10.1111/j.1398-9995.2012.02853.x
Patel NS, Fung SM, Zanichelli A, et al. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc. 2013;34:72-77. doi:10.2500/aap.2013.34.3620
Zingale LC, Castelli R, Zanichelli A, et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am. 2006;26:669-690. doi:10.1016/j.iac.2006.08.002
Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med. 1996;334:1666-1667. doi:10.1056/nejm199606203342510
Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012;379:474-481. doi:10.1016/s0140-6736(11)60935-5
Rosen FS, Pensky J, Donaldson V, et al. HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS. Science (80- ). 1965;148:957-958.
Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407-414. doi:10.2500/aap.2010.31.3394
Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:314-320. doi:10.1016/j.anai.2010.01.024
Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006;101:619-627. doi:10.1111/j.1572-0241.2006.00492.x
Grattan C, Saini S. Urticaria and Angioedema. In: Bolognia JL,Schaffer J, Cerroni L eds. Dermatology. Vol I. Elsevier; 2018:304-319.
Bork K, Gul D, Hardt J, et al. Hereditary angioedema with normal C1 inhibitor: clinical symptoms and course. Am J Med. 2007;120:987-992. doi:10.1016/j.amjmed.2007.08.021
Marcos C, Lopez Lera A, Varela S, et al. Clinical, biochemical, and genetic characterization of type III hereditary angioedema in 13 Northwest Spanish families. Ann Allergy Asthma Immunol. 2012;109:195-200.e2. doi:10.1016/j.anai.2012.05.022
Vitrat-Hincky V, Gompel A, Dumestre-Perard C, et al. Type III hereditary angio-oedema: clinical and biological features in a French cohort. Allergy. 2010;65:1331-1336. doi:10.1111/j.1398-9995.2010.02368.x
Donaldson VH, Rosen FS. ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C’1-ESTERASE. J Clin Invest. 1964;43:2204-2213. doi:10.1172/jci105094
Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-131. doi:10.1016/j.jaci.2004.06.047
Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308-320. doi:10.1016/j.jaci.2011.11.025
Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73:1575-1596. doi:10.1111/all.13384
Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22. doi:10.1186/1710-1492-6-22
Busse PJ, Farkas H, Banerji A, et al. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. BioDrugs. 2018. [Epub ahead of print] doi:10.1007/s40259-018-0325-y
Zotter Z, Veszeli N, Csuka D, et al. Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema. Orphanet J Rare Dis. 2014;9:205. doi:10.1186/s13023-014-0205-6
Myers SP, Kutcher ME, Rosengart MR, et al. Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. J Trauma Acute Care Surg. 2019;86:20-27. doi:10.1097/ta.0000000000002061
Grant JA, White M V, Li HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc. 2012;33:348-353. doi:10.2500/aap.2012.33.3585
Todos os artigos desta revista são de acesso aberto sob a licença internacional Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0).
